# Study Evaluating the Safety and Efficacy of CLONICEL® to Treat Children and Adolescents With Attention Deficit Hyperactivity Disorder (ADHD)

> **NCT00556959** · PHASE3 · COMPLETED · sponsor: **Addrenex Pharmaceuticals, Inc.** · enrollment: 236 (actual)

## Conditions studied

- Attention Deficit Disorder With Hyperactivity

## Interventions

- **DRUG:** high dose clonidine HCl sustained release
- **DRUG:** low dose clonidine HCl sustained release
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT00556959
- **Lead sponsor:** Addrenex Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-10
- **Primary completion:** 2008-08
- **Final completion:** 2008-08
- **Target enrollment:** 236 (ACTUAL)
- **Last updated:** 2010-03-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00556959

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00556959, "Study Evaluating the Safety and Efficacy of CLONICEL® to Treat Children and Adolescents With Attention Deficit Hyperactivity Disorder (ADHD)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00556959. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*